Pharmacokinetics (PK) Drug Interaction Study of Milademetan and Itraconazole or Posaconazole in Healthy Participants

Early Phase 1CompletedNCT03614455

Daiichi Sankyo36 enrolled

Overview

This will be an open-label, randomized, 3-treatment, 2-period, 2-sequence study in healthy subjects to evaluate the single-dose PK of milademetan when given as monotherapy and when administered with steady-state levels of the strong CYP3A4 inhibitors itraconazole or posaconazole. The duration of the study for each individual subject will be approximately 49 days from the start of Screening through Study Discharge. Subjects will remain in-house for up to 23 days, including 22 overnight stays.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Pharmacokinetics

Interventions

MilademetanDRUG

Milademetan 100 mg capsule for oral administration

ItraconazoleDRUG

Itraconazole (200 mg) oral solution (20 mL of 10 mg/mL)

PosaconazoleDRUG

Posaconazole (200 mg) oral suspension (5 mL of 40 mg/mL)

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Healthy participants with no clinically significant medical history or physical examination findings and who also meet all protocol-defined inclusion and exclusion criteria summarized as follows: Inclusion Criteria: * Has negative urine test for drugs of abuse, alcohol and tobacco * If female, is surgically sterile or postmenopausal * If male, agrees to protocol-defined contraceptive methods * Has adequate hematologic, hepatic, and renal function as defined by the protocol * Is able and willing to follow all study procedures * Has provided a signed informed consent Exclusion Criteria: * Is female who is pregnant or breastfeeding * Is unable to swallow oral medication * Is unable to follow study procedures * Has creatinine clearance \< 90 mL/min at screening * Is taking or has taken any medications or therapies outside of protocol-defined parameters * Has history of or a known allergic reaction to azole antifungal agents * Has any disease or condition that, per protocol or in the opinion of the investigator, might affect: 1. safety and well-being of the participant or offspring 2. safety of study staff

Locations (1)

Covance Clinical Research Unit, Inc.

Dallas, Texas, United States